This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Congenital Stenosis of Vena Cava


1. History

Congenital stenosis of the vena cava is a very rare lesion among congenital cardiovascular malformations and was first described in autopsy reports in the early 20th century. Clinically, because the clinical significance and treatment approach of superior vena cava (SVC) and inferior vena cava (IVC) stenosis differ, they have historically tended to be described separately.

Superior vena cava stenosis arises from both congenital and acquired causes; congenital cases are known to involve membranous stenosis due to abnormal vascular development or stenosis due to extrinsic compression. Inferior vena cava stenosis is one of the causes of Budd-Chiari syndrome, and membranous obstruction/stenosis at the hepatic vein inflow or within the inferior vena cava is reported relatively frequently in Asia (Korea, Japan, China, India).

The history of treatment changed greatly with the development of percutaneous balloon angioplasty and stent placement since the 1980s. Previously, surgical bypass was the only treatment option, but interventional procedures are now established as first-line treatment. In Korea, experience has accumulated with interventional treatment of Budd-Chiari syndrome, including membranous obstruction of the inferior vena cava.

2. Causes

Congenital stenosis of the vena cava can arise from the following causes:

Congenital stenosis of the superior vena cava (SVC):

Congenital stenosis of the inferior vena cava (IVC):

It may also occur as part of congenital malformations: inferior vena cava abnormalities may accompany asplenia/polysplenia, situs ambiguus, complex cardiac malformations, and others.

3. Genetics

Specific genetic causes of congenital stenosis of the vena cava have not yet been sufficiently elucidated.

Heterotaxy syndrome:

Membranous obstruction of the inferior vena cava (MOVC):

Associated congenital heart malformations:

For comprehensive genetic evaluation, chromosomal microarray and cardiovascular gene panel testing may be considered.

4. General epidemiology

Congenital stenosis of the vena cava is a very rare malformation, and accurate incidence data are lacking.

Congenital SVC stenosis: extremely rare, at the level of case reports, with no incidence statistics.

IVC membranous obstruction (MOVC, a cause of Budd-Chiari syndrome):

IVC abnormalities associated with complex heart malformations:

It is eligible for Special Copayment Reduction V150 in Korea, and appropriate specialized treatment is needed after diagnosis.

5. Pathophysiology

The pathophysiology of vena cava stenosis differs according to the site and degree of stenosis.

SVC stenosis:

IVC stenosis/membranous obstruction (MOVC):

6. Symptoms

Symptoms of vena cava stenosis differ according to the site and severity of stenosis.

Symptoms of SVC stenosis:

Symptoms of IVC stenosis/MOVC (Budd-Chiari type):

Congenital lesions often remain asymptomatic into adulthood and are discovered incidentally or during testing for other conditions. In particular, IVC membranous obstruction often presents in middle age as Budd-Chiari syndrome.

7. Signs

Physical examination findings:

Signs of SVC stenosis:

Signs of IVC stenosis:

Echocardiography/vascular ultrasound can confirm stenosis and flow abnormalities at the affected site.

8. Screening

Strategies for screening and early detection of congenital stenosis of the vena cava:

Screening for IVC stenosis/MOVC:

Screening for SVC stenosis:

IVC abnormalities associated with heart malformations:

Family history screening: family testing is considered when a specific genetic cause is identified.

9. Diagnosis

Confirmation of vena cava stenosis and pretreatment evaluation:

CT angiography (CTA):

MRI/MR angiography (MRA):

Venography:

Liver biopsy: used to assess the degree of liver fibrosis when reduced liver function or cirrhosis is suspected.

Blood tests: coagulation abnormalities (thrombophilia testing: factor V Leiden, PT20210A, protein C/S, antithrombin III, etc.) are evaluated to search for the cause of thrombosis.

10. Treatment

Treatment of vena cava stenosis is determined by the site and degree of stenosis and the clinical symptoms.

Treatment of IVC membranous obstruction (MOVC):

Treatment of SVC stenosis:

Management of Budd-Chiari complications:

11. Prognosis

The prognosis of vena cava stenosis differs according to the treatment method and the degree of liver function damage.

Prognosis after treatment of IVC membranous obstruction (MOVC):

Prognosis related to liver function:

Prognosis of SVC stenosis:

IVC abnormalities associated with complex heart malformations:

12. Prevention

Prevention of congenital stenosis of the vena cava focuses on preventing thrombotic complications and early diagnosis.

Thrombophilia screening and prevention:

Regular follow-up:

IVC abnormalities associated with complex heart malformations:

Prenatal diagnosis: in fetuses with suspected asplenia/polysplenia syndrome, IVC abnormalities are evaluated with fetal echocardiography to prepare postnatal measures.

13. References

  1. Okuda H, et al. Epidemiological and clinical features of Budd-Chiari syndrome in Japan. J Hepatol. 1995;22(1):1-9. PMID:7890710
  2. Plessier A, Valla DC. Budd-Chiari syndrome. Semin Liver Dis. 2008;28(3):259-269. PMID:18814077
  3. Han G, et al. Budd-Chiari syndrome: treatment outcome with long-term follow-up. J Vasc Interv Radiol. 2012;23(9):1166-1175. PMID:22921342
  4. Zhang CQ, et al. Treatment of Budd-Chiari syndrome: analysis of the benefit and defects of management strategies. J Gastroenterol Hepatol. 2004;19(12):1348-1354. PMID:15610311
  5. Darwish Murad S, et al. Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med. 2009;151(3):167-175. PMID:19414839
  6. Seijo S, et al. The role of heritable thrombophilic disorders in the etiology of Budd-Chiari syndrome. Hepatology. 2015;61(5):1655-1662. PMID:25620470
  7. Kim TK, et al. Membranous obstruction of the inferior vena cava in Korea. Cardiovasc Intervent Radiol. 1998;21(1):29-35. PMID:9449527
  8. Valla DC. Primary Budd-Chiari syndrome. J Hepatol. 2009;50(1):195-203. PMID:19014844
  9. Smalberg JH, et al. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis. Blood. 2012;120(25):4921-4928. PMID:23043069
  10. Garcia-Pagan JC, et al. TIPS for Budd-Chiari syndrome: long-term results and prognostics factors. J Hepatol. 2008;48(5):812-820. PMID:18331772